表紙
市場調査レポート

米国・ドイツ・スペインのポイントオブケア(POC)薬物乱用検査市場の分析:開業医/グループ検診、緊急治療室、外来治療センターの部門での詳細動向

Drugs of Abuse: A Analysis of the Point-of-Care Testing Market: US, Germany, Spain - Physician Offices, Emergency Rooms, Ambulatory Care Centers

発行 Venture Planning Group 商品コード 269910
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。

Local License: 同一事業所内

Back to Top
米国・ドイツ・スペインのポイントオブケア(POC)薬物乱用検査市場の分析:開業医/グループ検診、緊急治療室、外来治療センターの部門での詳細動向 Drugs of Abuse: A Analysis of the Point-of-Care Testing Market: US, Germany, Spain - Physician Offices, Emergency Rooms, Ambulatory Care Centers
出版日: ページ情報: 英文
概要

当レポートでは、米国・ドイツ・スペインの3ヶ国におけるポイントオブケア(POC)向けの薬物乱用検査用薬剤の市場について分析し、市場全体および部門別(開業医/グループ検診、緊急治療室、外来治療センターなど)の今後の市場動向や傾向、規制・技術の動向、既存・新規製品の市場機会、競争構造、今後の市場機会と課題といった情報を盛り込んで、概略以下の構成でお届けします。

イントロダクション

エグゼクティブ・サマリー

分散型検査の合理的根拠

  • 概要
  • 規制動向
  • 経済動向
  • 人口動向
  • 技術動向
  • 社会動向
  • 治療の品質
  • 防衛的医療
  • 品質管理(QC)の問題点

世界の市場・技術の概要

  • 概要
  • 検査方法
  • アンフェタミン
  • バルビツール酸系薬剤
  • ベンゾジアゼピン系薬剤
  • カンナビノイド/マリファナ
  • コカイン
  • リセリグ酸ジエチルアミド(LSD)
  • メタドン
  • メタカロン
  • アヘン剤
  • フェンシクリジン

世界のビジネス環境

米国市場

  • 市場概要
  • 開業医/グループ診療
  • 補助的医療施設
  • 外来治療センター

ドイツ市場

  • 市場概要
  • 市場構造
  • 市場のサマリー
  • 主要サプライヤーの試薬販売量・販売額の予測

スペイン市場

  • 市場概要
  • 市場構造
  • 市場のサマリー
  • 主要サプライヤーの試薬販売量・販売額の予測

分散型検査製品の設計基準

代替的な市場普及戦略

  • 内部開発
  • 共同事業協定
  • 大学との契約
  • 分散型検査市場の流通戦略
    • マーケティングのアプローチ
    • 製品の複雑性
    • 顧客の選好
    • 既存のサプライヤー
    • 新規参入サプライヤー
    • 流通業者の主な種類
    • 市場の細分化

潜在的な市場参入障壁とリスク

  • 市場の成熟化
  • コスト抑制
  • 競争
  • 最先端技術とその限界
  • 特許保護
  • 規制による抑制
  • 分散型検査市場の課題

図表一覧

目次
Product Code: VPCC4192

This new 194-page report from Venture Planning Group contains 22 tables, and provides a comprehensive analysis of the POC drugs of abuse testing market, including trends, dynamics, size, growth, regulatory requirements, technological trends, competitive landscape, and emerging opportunities for instrument and consumable suppliers. This report will help diagnostic product suppliers develop effective business, R&D and marketing strategies for the global POC abused drugs market.

Rationale

The growing economic pressures on hospitals, coupled with advances in diagnostic technologies, intensifying competition among suppliers and physicians, and changing consumer demands are shifting diagnostic testing from hospitals and commercial laboratories closer to the patient.
 
Market Segmentation Analysis

- Review of three POC market segments, including their dynamics, trends, structure,
  size, growth and major suppliers.
- Five-year test volume and reagent sales forecasts for drugs of abuse procedures
  by market segment:

- Physician Offices/Group Practices    
- Emergency Rooms       
- Ambulatory Care Centers 
       
- Analysis of drugs of abuse procedures

Competitive Assessments

- Assessments of major POC suppliers and emerging market entrants,
  including their sales, product portfolios, marketing tactics, joint ventures,
  and new products in R&D.

Strategic Recommendations

- Specific opportunities for new instruments and reagent systems with potentially
  significant market appeal during the next five years.
- Design criteria for POC testing products.
- Alternative business expansion strategies.
- Potential market entry barriers and risks.

Methodology

This report is based on a combination of primary and secondary sources of information, including review of the latest technical and business publications, manufacturer product literature, industry analyst reports, and Venture Planning Group's proprietary data files.

Table of Contents

Introduction

Executive Summary

Rationale for Testing Decentralization

  • 1. Overview
  • 2. Regulatory Trends
  • 3. Economic Trends
  • 4. Demographic Trends
  • 5. Technological Trends
  • 6. Social Trends
  • 7. Quality of Care
  • 8. Defensive Medicine
  • 9. Quality Control Issues

Worldwide Market and Technology Overview

  • 1. Overview
  • 2. Test Methodologies
  • 3. Amphetamines
  • 4. Barbiturates
  • 5. Benzodiazepines
  • 6. Cannabinoids/Marijuana
  • 7. Cocaine
  • 8. Lysergic Acid Diethylamide (LSD)
  • 9. Methadone
  • 10. Methaqualone
  • 11. Opiates
  • 12. Phencyclidine

Worldwide Business Environment

U.S.A.

  • A. Market Overview
    • 1. Business Environment
      • a. Health Care Expenditures
      • b. Cost Consciousness
      • c. Reimbursement
      • d. Industry Consolidation
      • e. Managed Care
        • PPO
        • HMO
      • f. Hospitals
      • g. Admissions
      • h. Length of Stay
      • i. Industry Diversification
      • j. Physician Demographics
      • k. Aging Population
        • More Chronic Illness
        • Disease Incidence
        • Susceptibility to latrogenesis
        • Multiple Illnesses Cases
      • l. Laboratory Regulations
    • 2. Market Structure
      • a. Hospitals
      • b. Commercial/Private Laboratories
  • B. Physician Offices/Group Practices
    • 1. Market Summary
    • 2. Market Structure
    • 3. Drugs of Abuse Test Volume and Sales Forecasts
  • C. Ancillary Hospital Locations
    • 1. Introduction
    • 2. Emergency Departments
      • a. Market Summary
      • b. Drugs of Abuse Test volume and Sales Forecasts
  • D. Ambulatory Care Centers
    • 1. Introduction
    • 2. Market Summary
    • 3. Market Structure
    • 4. Drugs of Abuse Test Volume and Sales Forecasts

Germany

  • A. Market Overview
  • B. Market Structure
  • C. Market Summary
  • D. Drugs of Abuse Test Volume and Sales Forecasts

Spain

  • A. Business Environment
  • B. Market Structure
  • C. Market Summary
  • D. Drugs of Abuse Test Volume and Sales Forecasts

Design Criteria for Decentralized Testing Products

Alternative Market Penetration Strategies

  • A. Internal Development
  • B. Collaborative Arrangements
  • C. University Contracts
  • D. Distribution Strategies for Decentralized Testing Markets
    • 1. Marketing Approaches
    • 2. Product complexity
    • 3. Customer Preference
    • 4. Established Suppliers
    • 5. Emerging Suppliers
    • 6. Major Types of Distributors
    • 7. Market Segmentation

Potential Market Entry Barriers and Risks

  • A. Market Maturity
  • B. Cost Containment
  • C. Competition
  • D. Technological Edge and Limitations
  • E. Patent Protection
  • F. Regulatory Constraints
  • G. Decentralized Testing Market Challenges

List of Tables

  • Major Companies Developing or Marketing Drugs of Abuse Tests
  • U.S.A., Physician Office/Group Practice Laboratories Forecast by Practice Size
  • U.S.A., Physician Offices/Group Practices Forecast by Type
  • U.S.A., Office-Based Physicians Forecast by Practice Type
  • U.S.A., Physician Offices/Group Practices Drugs of Abuse Test Volume Forecasts
  • U.S.A., Physician Offices/Group Practices Drugs of Abuse Reagent and Instrument Sales Forecast
  • U.S.A., Ancillary Hospital Locations Estimated Number
  • U.S.A., Ancillary Hospital Locations Annual Utilization
  • U.S.A., Hospital Emergency Departments Drugs of Abuse Test Volume Forecast
  • U.S.A., Hospital Emergency Departments Drugs of Abuse Reagent and Instrument Sales Forecast
  • U.S.A., Ambulatory Care Centers Estimated Number of Facilities and Patient Visits
  • U.S.A., Ambulatory Care Centers Most Frequent Diagnoses
  • U.S.A., Ambulatory Care Centers Drugs of Abuse Test Volume Forecast
  • U.S.A., Ambulatory Care Centers Drugs of Abuse Reagent and Instrument Sales Forecast
  • Germany, Laboratory Performing Diagnostic Tests by Market Segment
  • Germany, Physician Offices/Group Practices Drugs of Abuse Test Volume Forecast
  • Germany, Physician Offices/Group Practices Drugs of Abuse Reagent and Instrument Sales Forecast
  • Germany, Major Suppliers of Coagulation Diagnostic Products Estimated Market Shares
  • Spain, Laboratory Performing Drugs of Abuse by Market Segment
  • Spain, Ambulatory Care Centers Drugs of Abuse Test Volume Forecast
  • Spain, Ambulatory Care Centers Drugs of Abuse Reagent and Instrument Sales Forecast
  • Spain, Major Suppliers of Diagnostic Products Estimated Market Shares
Back to Top